Skip to Content
Merck
All Photos(1)

Key Documents

N2038

Sigma-Aldrich

Anti-NY-ESO-1 antibody, Mouse monoclonal

clone E978, purified from hybridoma cell culture

Synonym(s):

Anti-CTAG1, Anti-Cancer/Testis Antigen 1

Sign Into View Organizational & Contract Pricing


About This Item

MDL number:
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

Quality Level

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

E978, monoclonal

form

buffered aqueous solution

mol wt

antigen ~23 kDa

species reactivity

human

packaging

antibody small pack of 25 μL

concentration

~1 mg/mL

technique(s)

immunohistochemistry: suitable
indirect ELISA: suitable
western blot: 1-2 μg/mL using SKMel-37 total cell extract

isotype

IgG1

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... CTAG1B(1485)

General description

Monoclonal Anti-NY-ESO-1 (mouse IgG1 isotype) is derived from the hybridoma E978 produced by the fusion of mouse myeloma cells (SP2/0) and splenocytes from BALB/c mice immunized with human recombinant NY-ESO-1. The NY-ESO-1, also known as cancer/testis antigen 1 is expressed in normal testis and to a much lower extent in placenta, ovary and uterus.

Immunogen

recombinant human NY-ESO-1.

Application

Monoclonal Anti-NY-ESO-1 antibody produced in mouse has been used in enzyme linked immunosorbent assays (ELISA), immunoblotting and immunohistochemistry.
Monoclonal Anti-NY-ESO-1 is used as a probe to determine the presence and roles of Cancer/Testis Antigen 1 in humoral immune responses and a variety of cancers.

Biochem/physiol Actions

Cancer/testis (CT) antigens are the protein products of genes that are activated in a wide variety of tumors and can elicit autologous cellular and humoral immune responses. Their normal expression is restricted to male germ cells in the testis and they are not expressed in adult somatic tissues. Therefore, CT antigens are promising candidates for cancer immunotherapy. Approximately 20 CT antigens or antigen families have been identified to date. NY-ESO-1 is a CT protein to which cell-mediated immune response has been demonstrated. It is highly expressed in various types of cancers. For example, patients with melanoma contain tumor-infiltrating lymphocytes cells (TILs) that recognized NY-ESO-1 protein. The expression of genes encoding CT antigens was examined in sporadic medullary thyroid carcinoma. The expression of NY-ESO-1 was found in 65 percent of the samples and correlated with tumor recurrence in primary MTC tumors. Furthermore, high frequency of expression was found in breast cancer especially in benign lesions and in multiple myeloma. Due to its wide expression in different cancers, NY-ESO-1 protein was used as a vaccine in cancer patients.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Shanshan W Howland et al.
Journal of immunotherapy (Hagerstown, Md. : 1997), 31(7), 607-619 (2008-07-05)
Saccharomyces cerevisiae stimulates dendritic cells (DCs) and represents a promising candidate for cancer vaccine development. Effective cross-presentation of antigen delivered to DCs is necessary for successful induction of cellular immunity. Here, we present a yeast-based vaccine approach that is independent
Elizabeth Shurell et al.
Oncotarget, 7(45), 72860-72867 (2016-09-23)
Immunotherapy targeting cancer-testis antigen NY-ESO-1 shows promise for tumors with poor response to chemoradiation. Malignant peripheral nerve sheath tumors (MPNSTs) and liposarcomas (LPS) are chemoresistant and have few effective treatment options. Materials Methods: Using a comprehensive tissue microarray (TMA) of
Iris Scherwitzl et al.
Molecular therapy oncolytics, 9, 51-63 (2018-07-11)
Oncolytic viruses represent a promising form of cancer immunotherapy. We investigated the potential of Sindbis virus (SV) for the treatment of solid tumors expressing the human cancer testis antigen NYESO-1. NYESO-1 is an immunogenic antigen frequently expressed in numerous cancers
Shugo Ueda et al.
Oncotarget, 9(89), 35997-36011 (2018-12-14)
MAGE-A4 antigen is a cancer-testis antigen that is frequently expressed in tumor tissues. Cholesteryl pullulan (CHP) is a novel antigen delivery system for cancer vaccines. This study evaluated the safety, immune responses and clinical outcomes of patients who received a
The cancer-testis gene, NY-ESO-1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ
Satie AP, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology, 82(6), 775-775 (2002)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service